PBD Dimer Linker Design for ADC Aggregation and Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) face challenges in achieving maximal efficacy with minimal toxicity due to non-selective drug delivery, aggregation issues of PBD dimers, and instability of linkers, which affect the specificity and effectiveness of pyrrolobenzodiazepine (PBD) compounds when conjugated to cell binding agents.
Innovation Solution
Development of a PBD dimer with a smaller, less lipophilic C2 substituent and a cleavable protecting group to prevent aggregation, linked through the N10 position, allowing for stable extracellular conjugation to cell binding agents and targeted intracellular release of an active PBD compound via enzyme cleavage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PBD dimers are conjugated to cell binding agents, then targeted delivery to tumors is achieved, but aggregation occurs reducing effectiveness
Solution Approach 1:
The patent modifies the C2 substituent parameters of the PBD dimer structure, specifically using smaller, less lipophilic groups (such as fluorinated phenyl or propylene) instead of larger lipophilic groups. This parameter change reduces the tendency of PBD dimers to aggregate while maintaining their DNA binding capability and conjugation functionality.
2Reliability
If linkers are used to connect PBD to cell binding agents, then targeted delivery is enabled, but linker instability causes premature drug release and toxicity
Solution Approach 1:
The patent introduces a stable linker structure as an intermediary component between the PBD dimer and cell binding agent. This linker contains a cleavable protecting group that remains stable in extracellular environments but can be selectively removed by intracellular enzymes, thereby mediating controlled drug release only at the target site.
Solution Approach 2:
The patent applies preliminary protection by attaching a cleavable protecting group to the linker before conjugation. This protecting group prevents premature drug release during circulation and conjugation, and is designed to be removed only under specific intracellular conditions, ensuring the drug remains inactive until it reaches the target.
3Adaptability or versatility
If N10 position is used for linker attachment, then conjugation flexibility is improved, but cross-reactions occur during synthesis
Solution Approach 1:
The patent applies preliminary protective group chemistry to the N10 position before conjugation. A protecting group is attached to the N10 position to prevent cross-reactions during synthesis, and this protecting group is subsequently removed under controlled conditions to enable specific linker attachment, thereby preventing unwanted side reactions while maintaining conjugation flexibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach enhances the stability and specificity of PBD conjugates, ensuring effective delivery and cytotoxic effects while minimizing toxicity and aggregation, thereby improving the therapeutic index of PBD-based ADCs.
Implementation Method 1
linked through the N10 position, allowing for stable extracellular conjugation to cell binding agents and targeted intracellular release of an active PBD compound via enzyme cleavage
Data Source
Figure 1
AI summary
RJW/FP7067259 150 ABSTRACT A compound which is selected from A: A O OO O O O I O NH O O O O O O O O N H N H N H OO OH H O N N OO H N N B: 5 B O OO O O O Br O NH O O O O O O O O N H N H N H OO OH H O N N OO H N N; and C C O O N H N H O N H OO OO O O N O OO O O O O NH O O O O O O O O N H N H N H OO OH H O N N OO OH H N N; and salts and solvates thereof.